by Francisca Peixoto | Dec 22, 2021 | Uncategorized
As the year comes to a close, LifeLink Ventures releases its Annual Biotech Report. We wish to connect private investors with emerging technologies that address global health challenges. To do so, first we must bring our investors closer to the biotech world. Learn...
by Francisca Peixoto | Jun 16, 2021 | Uncategorized
Our portfolio company CEBINA was founded with the aim of creating, nurturing, and promoting early-stage life sciences companies in central Europe. CEBINA incubates and accelerates promising projects in the biotech field. Now, CEBINA has joined forces with the...
by Francisca Peixoto | Mar 18, 2021 | Uncategorized
For our latest newsletter we have compiled a summary of the efficacy and side effects for the first generation of Covid-19 vaccines. We aim to provide a reliable source of biotechnological information for the public. To access the full document please click here:...
by feryadmin | Jan 20, 2021 | Uncategorized
Accure Therapeutics, one of our portfolio companies, is starting 2021 strong by incorporating five neurology world-class experts into their scientific advisory board. #neurology #clinicalstudies #brain #opticneuritis #parkinsonsdisease #multiplesclerosis...
by feryadmin | Dec 10, 2020 | Uncategorized
Join us today at 4:50pm CET for a session about “Life Sciences for Impactful Transition” at the Nordic Impact Business Summit. Full day streaming (open to anyone): https://lnkd.in/eCvyH6M Moderated by: Frederik van Deurs, CEO, Green Innovation Group [DK] Guests...
by feryadmin | Nov 9, 2020 | Uncategorized
Eveliqure Biotechnologies GmbH today announces the award of a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID), contract #75N93020C00048 with the intent to fund the development of its vaccine candidate, ShigETEC, through...